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ABSTRACT
Bronchial asthma (BA) is characterized by infiltration of
the respiratory tracts by eosinophils. A wide variety of
adhesion molecules is involved in the binding of
eosinophils to the vascular endothelium and their sub-
sequent transmigration from the circulation to the
airways, while little is known about CD44 expression
on eosinophils. In the present study we introduce a
novel staining combination with which surface markers
on eosinophils can be analyzed without purification
prior to staining and examined whether the expression
of CD44 on peripheral blood eosinophils could be
monitored as a marker of the control of BA. Staining of
eosinophils with anti-CD16 and anti-VLA-4 mono-
clonal antibodies enabled us to delineate eosinophils
as VLA-4highCD16- cells from other leukocyte popu-
lations in the whole blood. CD44 was constitutively
expressed on resting eosinophils and expression
increased following cytokine-mediated activation. In
all BA patients examined, CD44high eosinophils were
enriched in sputum relative to peripheral blood,
indicating that eosinophils in sputum were more
activated than those in the blood. By comparing the
extent of CD44 expression on blood eosinophils from
poorly controlled and well-controlled asthma patients,
we unexpectedly found that the density of CD44
expression is lower on blood eosinophils from the
poorly controlled group. Thus, the extent of CD44
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expression on blood eosinophils defined as VLA-
4highCD 16- cells is a novel marker indicative of the
management of BA.
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INTRODUCTION
Bronchial asthma (BA) is an inflammatory disease of the
respiratory tracts characterized by infiltration of the airways
by a variety of inflammatory cells, including eosinophils
and lvmphocvtes.':" Adhesion molecules expressed on
endothelial and inflammatory cells playa pivotal role in the
initial stage of the translocation process.v" CD44 was an
adhesion molecule involved in lymphocyte transmigration
from the circulation to inflammatory sites? or to the
thymus." although the CD44 expression on eosinophils has
not been studied extensively.
Eosinophils comprise a minor leukocyte population in
peripheral blood. Changes in the number and proportion
of blood eosinophils have been used as indicators of the
asthmatic condition.? Characteristic staining of eosino-
phil granules by various dyes enables discrimination of
this subset from other leukocytes; however, the lack of
specific surface markers for eosinophils has hampered
the easy identification of the population by flow cyto-
metry. No surface markers on eosinophils are monitored
as a good marker of the course of deterioration and
amelioration of BA.
In the present report we introduce a novel staining
combination with which surface markers on eosinophils
can be analyzed without purification prior to staining and
examined whether the extent of CD44 expression on
eosinophils correlated with the control of BA. CD44
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expression on eosinophils increased following cytokine-
mediated activation. In BA patients, CD44high eosinophils
were enriched in sputum relative to peripheral blood.
Surprisingly, the level of CD44 expression on blood
eosinophils was lower in poorly controlled patients
compared with well-controlled patients. Thus, the level of
CD44 expression on eosinophils could be a useful novel
marker indicative of the management of BA.
METHODS
Subjects
Asthmatic patients who had been treated at the Tohoku
University Hospital were chosen as subjects. The patients,
with various BA severity, were separated into two groups
based on peak expiratory flow (PEF), measured using the
Assess Peak Flow Meter (HealthScan Products Inc., Cedar
Grove, NJ, USA) at the time of blood sampling. Patients
with PEF values of over 80% or less than 60% of the
expected maximal value were categorized as well-
controlled or poorly controlled, respectively. The expected
maximal PEF was determined for each patient according
to the manufacturer's data table. The mean (± SD) daily
doses of corticosteroids taken by each patient in the weil-
and poorly controlled groups are as follows: oral
prednisolone at 1.50 ± 2.41 and 0.58 ± 1.45 mg/day,
respectively; inhaled beclomethasone at 850 ± 845 and
815 ± 600 ~g/day, respectively. No significant difference
in treatment was noted between the two groups.
Reagents used for flow cytometry
An anti-VLA-4 (CD49d) monoclonal antibody was
kindly provided by Dr K Miyake (Saga Medical
University]."? The anti-VLA-4 monoclonal antibody
(mAb) was partially purified from ascites by precipitation
with 40% saturated ammonium sulfate and was
conjugated to fluorescein isothiocyanate (FITC; Sigma
Chemical Co., St Louis, MO, USA) in our laboratory.
Phycoerythrin (PE)-conjugated anti-CD44, biotinylated
anti-CD16, Quantum Red-conjugated streptavidin and
propidium iodide were all purchased from Sigma
Chemical Co.
Preparation of blood eosinophils and flow
cytometry
Heparinized whole blood cells were centrifuged in
dextran to remove red blood cells. The resulting leuko-
cyte populations (2 X 10 6 cells) were stained with anti-
VLA-4-FITC, anti-CD44-PE, anti-CD 16-biotin and
streptavidin-Quantum Red. Dead cells were excluded
from analysis by propidium iodide staining. Stained cells
were analyzed using FACScan (Becton Dickinson,
Cockeysville, MD, USA). Monocyte and lymphocyte
populations were discriminated by forward and side-
scatter properties and were excluded from analysis. The
remaining granulocyte population was composed
primarily of neutrophils in addition to eosinophils.
Eosinophils could be selectively acquired by gating on
VLA-4 ". CD 16- cells because neutrophils are VLA-4~,
CD 16 + .1113 By this staining and gating combination,
eosinophils comprising greater than 2% of whole
leukocyte counts could be reproducibly demarcated
from other leukocyte populations without eosinophil
purification prior to staining. The stability and repro-
ducibility of the flow cytometry analysis was verified by
running fluorescinated calibration beads (Polysciences
Inc., Warrington, PA, USA) before each analysis. Results
are expressed as the mean fluorescence intensity (MFI).
Preparation of sputum eosinophils
Sputa expectorated spontaneously or induced by 10 min
inhalation of 3% NaCI aerosol were collected from BA
patients with varying PEF values. The obtained sputa were
mixed with three volume of Sputasol (Unipath Ltd,
Hampshire, England), shaken for 30 min at room
temperature, filtered through nylon mesh to remove
debris and used for staining. Pretreatment of eosinophils
with Sputasol did not alter the level of CD44 expression
(data not shown).
Activation of eosinophils in vitro
Blood taken from normal volunteers was depleted of
erythrocytes, as described earlier, and was centrifuged
through lymphocyte separation medium (Organon
Teknita Corp., Durham, NC, USA) to remove mono-
nuclear cells. The enriched granulocyte population,
including neutrophils and eosinophils, was cultured at
a concentration of 5 X 10 6 /mL in the presence of
titrated concentrations of granulocyte-macrophage
colony stimulating factor (GM-CSF), interleukin (IL)-3
or IL-5. These cytokines were purchased from R&D
Systems (Minneapolis, MN, USA). After 24 h, cells
were harvested, stained and analyzed as described
earlier.
CD44 ON EOSINOPHILS IN BRONCHIAL ASTHMA 31
RESULTS
Establishment of a novel method to demarcate
blood eosinophils by flow cytometry
We started by establishing a method by which eosinophils
could be differentiated from among heterogeneous
blood leukocyte populations by flow cytometry. The three
distinct populations of peripheral blood leukocytes,
lymphocytes, monocytes and granulocytes, were differen-
tiated by forward- and side-scatter properties and a gate
was set to exclude lymphocytes and monocytes from
analysis (Fig. 1a). The remaining granulocyte population
could be clearly divided into two subpopulations based
on the expression of CD 16 and VLA-4 (CD49d; Fig. 1b).
Neutrophils express high levels of CD 16 and are
negative for VLA-4 expression, while eosinophils are
CD16- and VLA_4+. 12, 13 The validity of this method for
eosinophil identification was confirmed with experiments
using highly purified eosinophils. Forward- and side-
scatter values for the eosinophils did not exceed the limits
of the granulocyte gate (Fig. 1c). Staining of the purified
eosinophils with anti-VLA-4 and anti-CD 16 mAbs verified
this method of eosinophil identification, as the majority of
eosinophils were positive for VLA-4 expression and
negative for CD16 expression (Fig. 1d). By means of this
method, eosinophils comprising greater than 2% of
peripheral leukocytes could be reproducibly isolated
without prior purification steps (data not shown). In the
following experiments, eosinophils were stained with anti-
CD44 in addition to anti-CD 16 and anti-VLA-4 and
CD44 expression on gated eosinophils was examined.
Increased expression of CD44 on activated
eosinophils
To determine the effects of pro-inflammatory cytokines on
the CD44 expression of eosinophils, we cultured peri-
pheral blood granulocytes prepared from healthy donors
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Fig. 1 Selective acquisition of
eosinophils by flow cytometry. (a) Dot
plot analysis of whole blood leuko-
cytes is shown. Forward scatter/side
scatter gating (granulocyte gate) was
used to select a granulocyte fraction.
(b) The correlation between VLA-4 and
CD 16 expression for the granulocyte
fractions identified in (a). A VLA-4+,
CD16- fraction (eosinophil gate) was
acquired for analysis of eosinophils
using a FACScan. (c) Highly purified
eosinophils from healthy subjects were
analyzed by flow cytometry. The
purified eosinophils fell precisely
within the granulocyte gate. (d) The
purified eosinophils were VLA-4".
CD 16- cells, which verified the
propriety of the eosinophil gate in (b).
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Fig. 2 Increased expression of
C044 on eosinophils activated by
cytokines. Human blood eosinophils
prepared from healthy subjects were
cultured for 24 h in the presence of
titrated concentrations of interleukin
(IL)-S (a), IL-3 (b) and granulo-
cyte-macrophage colony stimulating
factor (c). The C044 expression on
the activated eosinophils was deter-
mined by flow cytometry. Individual
points represent the mean ± SO of
triplicate cultures. MFI, mean fluor-
escence intensity.
Activated eosinophils in peripheral blood were
reduced in poorly controlled asthmatic
patients
Increased numbers of eosinophils migrate into the
respiratory tracts in exacerbated disecse.':' This fact led us
to speculate that blood eosinophils may be more acti-
vated in exacerbated compared with well-controlled cBA
and that this increased activation would be reflected by
increased CD44 expression. To examine this hypothesis,
CD44 expression was compared on peripheral blood
eosinophils from BA patients with well-controlled (PEF >
80% expected value) and exacerbated (PEF < 60%
expected value) disease. The level of CD44 expression on
peripheral blood eosinophils from well-controlled patients
ranged from 45.0 to 124.6 MFI, with a mean (± SD)
of 73.4 ± 23.2 MFI (Fig. 4a). This result was almost
or GM-CSF (Fig. 2c). Thus, eosinophils, in an activated
state, were found to express increased levels of CD44.
Enrichment for CD44 high eosinophils in sputum
relative to peripheral blood
We compared the level of the CD44 expression on
eosinophils prepared from sputum to that of peripheral
blood eosinophils. In all BA patients with varying PEF
values, CD44 expression on eosinophils from sputum
was higher than that of peripheral blood. The average
MFI of CD44 on sputum eosinophils (95.1 ± 26.1) was
significantly higher than that of blood eosinophils (72.5
± 11.0; P < 0.01; Fig. 3). This result indicates that
eosinophils are more activated in sputum than in the
peripheral blood of asthmatic patients.
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Fig. 3 Enrichment of C044 high activated eosinophils in
sputum from asthmatic patients. Leukocytes from the sputum
and peripheral blood of asthmatic patients with various peak
expiratory flow values were stained with a combination of anti-
VLA-4, anti-C044 and anti-C016 monoclonal antibodies and
the expression of C044 on gated eosinophils was compared in
each patient (e-e). The mean (.) ± SO(-) of each group is
also shown. The C044 expression on sputum eosinophils was
significantly higher than that on blood eosinophils (P < 0.01;
paired t-test). MFI, mean fluorescence intensity.
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in the presence of titrated concentrations of IL-5, IL-3 or
GM-CSF for 24 h and examined the expression of CD44
on eosinophils by flow cytometry. Eosinophils constitu-
tively expressed CD44 and expression was increased in a
dose-dependent manner by IL-5 (Fig. 2a), IL-3 (Fig. 2b)
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Fig. 4 A decrease in activated
peripheral eosinophils in exacerbated
asthmatic patients. (a) Peripheral blood
eosinophils from either well-controlled
asthmatic subjects (> 80% expected
peak expiratory flow; PEF) or poorly
controlled subjects « 60% expected
PEF) were analyzed for CD44 expression
by flow cytometry. The expression of
CD44 on gated eosinophils in each
patient (e) and the mean (.) ± SD (-)
of each group is shown. It should be
noted that CD44 expression on
peripheral eosinophils was lower in
exacerbated asthmatic patients than in
well-controlled patients (P < 0.002). (b)
The number of peripheral blood
eosinophils between the two groups was
compared. No difference was noted.
MFI, mean fluorescence intensity.
comparable to that of normal subjects (67.7 ± 18.1
MFI). In sharp contrast, the level of CD44 expression on
peripheral blood eosinophils from poorly controlled
patients was significantly lower (P < 0.002), with an
average MFI of 48.3 ± 7.9 and a range of 32.1-61.8.
There was not a significant difference in the mean number
of peripheral blood eosinophils between well-controlled
(410 ± 328) and poorly controlled (403 ± 408) groups
(Fig. 4b). Thus, we found that eosinophils in peripheral
blood from poorly controlled patients were in a less active
state than those from well-controlled patients, with respect
to CD44 expression. This result indicates that the extent of
CD44 expression on blood eosinophils could be a novel
marker indicative of the management of BA.
DISCUSSION
One of the characteristic features of BA is pathogenic
invasion of the respiratory tract by eosinophils that are
lured from the circulction.!" Activation of eosinophils in
response to cytokines such as IL-3, IL-S or GM_CSF15-17
leads to the increased expression of adhesion molecules,
including LFA-1 and Mac-1, which is an essential step in
the transmigration from circulation to respiratory tract.
CD44, an adhesion molecule specific for hyaluronic acid,
is known to be expressed on various leukocyte populations.
Its critical role in lymphocyte homing to inflammatory sites/
and the thymus" has been well documented, while little is
known about CD44 expression on eosinophils.
In the present report we examined CD44 expression on
eosinophils from BA patients. CD44 is constitutively ex-
pressed on eosinophils and its expression level increases
following activation by cytokines. Because a higher
degree of respiratory tract infiltration by eosinophils is
observed in exacerbated BA compared with well-
controlled disease, we originally speculated that CD44
expression on blood eosinophils would be higher in
poorly controlled asthmatic patients than in well-con-
trolled patients. Surprisingly, we found that this is not the
case. CD44 levels on blood eosinophils were lower in
cases of poorly controlled disease than in well-controlled
subjects, indicating a reduction of activated blood
eosinophils in exacerbated BA. This result could be at
least in part ascribed to the enhanced transmigration of
the activated, CD44high eosinophils to the respiratory
tract, because eosinophils in sputum expressed higher
levels of CD44 than those in peripheral blood for all BA
patients examined. The enhanced accumulation of acti-
vated eosinophils in airways with a concomitant decrease
in peripheral blood implies that increased expression of
adhesion molecules on endothelium in the case of
exacerbated disease would facilitate transmigration of
activated eosinophils to local inflammatory sites while
leaving behind unactivated eosinophils in the blood. A
similar shift of activated cells to the airway was reported
by Barnes et 0/., who described a fall in peripheral blood
counts of activated CD4 and CD8 T lymphocytes with
corresponding increases in the oirwov.!" The difference in
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CD44 expression between poorly controlled and well-
controlled groups was not due to differences in medi-
cation. Patients were separated into two groups on the
basis of the PEF values at the time of blood sampling,
which reflected the control but not the severity of the
disease, and, therefore, there was no significant dif-
ference in treatment between two groups.
In exacerbated BA, the activated eosinophils were
reported to increase in the peripheral blood, which was
reflected in an increase in the serum level of eosinophilic
cationic protein (ECP).19,20 This observation appears
contradictory to our finding that eosinophils in the
peripheral blood were less activated in poorly controlled
patients with respect to CD44 expression. However, these
discrepant findings could be reconciled if serum ECP
derived from airway inflammatory foci where ECP was
released from activated eosinophils.
The number of blood eosinophils has been used as an
indicator of the asthmatic condition." In the present study,
we suggest that CD44 expression on blood eosinophils is
also a diagnostic indicator of BA. In this regard, it is useful
to monitor and compare the extent of blood eosinophil
CD44 expression in each individual throughout the course
of disease progression and amelioration. Levels of blood
eosinophil expression clearly increased following treatment
of an asthma attack in two cases examined (data not
shown). In both cases, the restoration of CD44 high
eosinophils in blood lagged behind the improvement in
PEF (data not shown). Recurrence of inflammatory
responses in the respiratory tract could also be heralded by
decreased levels of blood eosinophil CD44 expression.
Further studies are required to analyze this issue.
In the present study, we were able to reproducibly and
accurately examine the surface phenotype on eosinophils
without purification prior to staining. The method of direct
staining of whole leukocyte populations for analysis of
eosinophil could have advantages over gradient density
based purification procedures that may lead to removal of
an activated, low-density eosinophil fraction that could be
critical to disease. In addition, this method is simpler and
more time effective. The method described here enabled
us to obtain reproducible data for populations in which
eosinophils comprised at least 2% of total leukocytes.
A major ligand of CD44 is hyaluronic acid, which is a
constituent of the extracellular matrix. The importance of
CD44 function in various processes, including tumor
rnetostcsis.?' T lymphocyte migration to inflammatory
sites? and T lymphocyte precursor homing to the thvrnus,"
has been demonstrated. Signals through CD44 were
reported to stimulate functions of lymphocytes and NK
cells.22,23 Of particular interest is the reported involvement
of CD44 in eosinophil development from bone marrow
precursors." suggesting the existence of possible stimul-
atory signals transmitted by CD44. In this regard, the
increased expression of CD44 on activated eosinophils
may suggest that CD44 signaling is involved in adhesion
and transmigration. The verification in the present report
of an inverse relationship between CD44 expression on
blood eosinophils and the extent of BA management
implies that CD44 may be a primary adhesion molecule
required for eosinophil transmigration.
REFERENCES
Corrigan CJ, Hartnell A, Kay AB. T-Iymphocyte activation
in acute severe asthma. Lancet 1988; i: 1129-32.
2 Azzawi M, Bradley B, Jeffery PK et 0/. Identification of
activated T lymphocytes and eosinophils in bronchial
biopsies in stable atopic asthma. Am. Rev. Respir. Dis.
1990; 142: 1407-13.
3 Walker C, Kaegi MK, Braun P, Blaser K. Activated T cells
and eosinophilia in bronchoalveolar lavages from subjects
with asthma correlated with disease severity.J. AllergyC1in.
Immunol. 1991; 88: 935-42.
4 Corrigan CJ, Kay AB. T cells and eosinophils in the patho-
genesis of asthma. Immunol. Today 1992; 13: 501-7.
5 Springer TA. Traffic signals for lymphocyte recirculation
and leukocyte emigration: The multistep paradigm. Cell
1994; 76: 301-14.
6 Reed CEo The importance of eosinophils in the
immunology of asthma and allergic disease. Ann. Allergy
1994; 72: 376-80.
7 Camp RL, Scheynius A, Johansson C, Pure E. CD44 is
necessary for optimal contact allergic responses but is not
required for normal leukocyte extravasation. J. Exp. Med.
1993; 178: 497-507.
8 Lesley J, Hyman R, Schulte R. Evidence that the Pgp- 1
glycoprotein is expressed on thymus-homing progenitor
cells of the thymus. Cell. Immunol. 1985; 91: 397-403.
9 Bousquet J, Chanez P, Lacoste JY et 0/. Eosinophilic
inflammation in asthma. N. Engl. J. Med. 1990; 323:
1033-9.
10 Miyake K, Weissman IL, Greenberger JS, Kincade PW.
Evidence for a role of the integrin VLA-4 in lyrnpho-
hemopoiesis. J. Exp. Med. 1991; 173: 599-607.
11 Hansel TT, de Vries IJM, Iff T et 0/. An improved
immunomagnetic procedure for the isolation of highly
purified human blood eosinophils. J. Immunol. Methods
1991; 145: 105-10.
12 Walsh GM, Mermod JJ, Hartnell A, Kay AB, Wardlaw AJ.
Human eosinophil, but not neutrophil, adherence to IL-1
stimulated human umbilical vascular endothelial cells is
a4~1 (very late antigen-4)-dependent. J. Immunol. 1991;
146: 3419-23.
13 Schleimer Rp, Sterbinsky SA, Kaiser J et 0/. IL-4 induces
adherence of human eosinophils and basophils but not
neutrophils to endothelium: Association with expression of
VCAM-1. J. Immuno/. 1992; 148: 1086-92.
14 Page C. Asthma as a chronic inflammatory disease and
implications for future therapy. Ann. Allergy 1992; 69:
251-60.
15 Lopez AF, Sanderson CJ, Gamble JR,Campbell HD, Young
IG, Vadas MA. Recombinant human interleukin 5 is a
selective activator of human eosinophil function. J. Exp.
Me~ 1988; 167: 219-24.
16 Yamaguchi Y, Hayashi Y, Sugama Y et 01. Highly purified
murine interleukin 5 (IL-5) stimulates eosinophil function
and prolongs in vitro survival. J. Exp. Med. 1988; 167:
1737-42.
17 Rothenberg ME, Owen WF Jr, Silberstein DS et 01.
Human eosinophils have prolonged survival, enhanced
functional properties, and become hypodense when
exposed to human interleukin 3. J. C1in. Invest. 1988;
81: 1986-92.
18 Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF,
Barnes PJ. Immunomodulation by theophylline in asthma:
C044 ON EOSINOPHILS IN BRONCHIAL ASTHMA 35
Demonstration by withdrawal of therapy. Am. J. Respir. Crit.
Care Med. 1995; 151: 1907-14.
19 Numao T, Fukuda T, Hirata A et 0/. Eosinophil cationic
protein in patients with bronchial asthma. Jpn. J. Allergy
1991; 41: 1672-8.
20 Motojima S, Akutsu I, Fukuda T, Makino S. Clinical signifi-
cance of measuring levels of sputum and serum ECP and
serum IL-5 in bronchial asthma. Allergy1993; 48: 98-106.
21 Gunthert U, Hofmann M, Rudy W et 0/. A new variant of
glycoprotein CD44 confers metastatic potential to rat
carcinoma cells. Cell 1991 ; 65: 13-24.
22 Lesley J, He Q, Miyake K, Hamann A, Hyman R, Kincade
PW. Requirements for hyaluronic acid binding by CD44:
Role for the cytoplasmic domain and activation by
antibody. J. Exp. Med. 1992; 175: 257-66.
23 Galandrini R, De-Maria R, Piccoli M, Frati L, Santoni A.
CD44 triggering enhances human NK cell cytotoxic
functions. J. Immuno/. 1994; 153: 4399-407.
24 Hamann KJ, Dowling TL, Neeley Sp' Grant JA, Leff AR.
Hyaluronic acid enhances cell proliferation during
eosinopoiesis through the CD44 surface antigen. J.
Immunol. 1995; 154: 4073-80.
